Brazil to export vaccine against measles, rubella

October 28, 2013

Brazil will produce a combined vaccine against measles and rubella exclusively for export to poor countries, mainly in Africa, its health minister said Monday.

Alexandre Padilha said the aim was to produce 30 million doses by 2017 for sale at a price of 54 US cents each. Currently such vaccines are made only in India.

Padilha made the announcement at an event in Rio where he announced that the government was inking an investment deal with the US Bill & Melinda Gates foundation to develop the .

He said his ministry would invest $727 million in construction of a state-of-the pharmaceutical plant at the Bio-Manguinhos Institute, a government institution located in Rio.

"This plant will generate employment, revenue, know-how, research and technological innovation in this country," he added.

"The agreement which we are signing provides more investments and buying guarantees, which makes it possible to export at the lowest cost," he said.

The Gates Foundation is meanwhile allocating $1.1 million for the project.

Measles was eradicated in Brazil in 2000 and (or German measles) in 2009.

But the diseases remain endemic in some countries.

In 2011, 158,000 people died of around the world, most of them in , according to data from the World Health Organization.

Meanwhile Carlos Gadelha, the health ministry's science and technology secretary said Latin America's dominant economic power also hopes to make headway toward developing the pentavalent vaccine and a vaccine against dengue fever.

The pentavalent vaccine simultaneously provides protection against five life threatening diseases - Diphtheria, Pertussis, Tetanus, Hepatitis B and Hib (Haemophilus influenza type b).

Explore further: Timing of first dose of measles vaccine questioned

Related Stories

Timing of first dose of measles vaccine questioned

October 21, 2013
(HealthDay)—Children who receive the first dose of a two-dose schedule of measles vaccine at 12 to 13 months compared with 15 months or later have a greater risk of developing measles, according to a study published online ...

Vaccine coverage high in U.S., but measles outbreaks a concern: CDC

September 13, 2013
(HealthDay)—Vaccination rates among America's children remain high, despite a serious resurgence of measles among unvaccinated children and adults, health officials reported Thursday.

Measles deaths fall by over 70% in last decade, WHO reports

January 17, 2013
The global number of measles deaths dropped by 71 percent between 2000 and 2011 largely thanks to a boost in vaccination efforts, the UN World Health Organisation said Thursday.

Study finds earlier is better for measles immunization first dose

October 14, 2013
Children receiving measles-containing vaccines at 12-15 months of age have a lower increased risk of fever and seizures than those who receive them at 16-23 months of age, according to a new Kaiser Permanente study published ...

Man dies as UK measles epidemic spreads

April 19, 2013
U.K. authorities say a 25-year-old man is suspected to have died from measles as an epidemic continues to sweep across south Wales.

Vaccine confers long-term protection against cholera

October 16, 2013
A clinical study published in the Lancet Infectious Diseases shows for the first time that an oral cholera vaccine (ShancholTM) provides sustained protection against cholera in humans for up to five years. The study showed ...

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.